{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:55:44Z","timestamp":1790704544902,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007241","name":"Universite Paris-Saclay","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ejca.2024.114020","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T07:10:56Z","timestamp":1710573056000},"page":"114020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients"],"prefix":"10.1016","volume":"202","author":[{"given":"R\u00e9my","family":"Barbe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younes","family":"Belkouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Menu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemence","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Kind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Harguem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lama","family":"Dawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joya","family":"Hadchiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatine","family":"Selhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Billet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambroise","family":"Bertin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Littisha","family":"Lawrance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Balleyguier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Henry","family":"Cournede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Lassau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-7095","authenticated-orcid":false,"given":"Thierry","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114020_bib1","first-page":"1","article-title":"Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability\/mismatch repair deficiency in 2022","volume":"42","author":"Andr\u00e9","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejca.2024.114020_bib2","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.114020_bib3","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz LA","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114020_bib4","first-page":"136","article-title":"Deficient mismatch repair\/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment","volume":"175","author":"Taieb","year":"2022","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"10.1016\/j.ejca.2024.114020_bib5","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.annonc.2022.06.008","article-title":"Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142","volume":"33","author":"Andr\u00e9","year":"2022","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2024.114020_bib6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114020_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001499","article-title":"RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study","volume":"8","author":"Cohen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.114020_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114020_bib9","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study","author":"Andre","year":"2024","journal-title":"ASCO GI"},{"key":"10.1016\/j.ejca.2024.114020_bib10","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.114020_bib11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2022.06.055","article-title":"An artificial intelligence model predicts the survival of solid tumour patients from imaging and clinical data","volume":"174","author":"Schutte","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114020_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.982790","article-title":"Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume","volume":"12","author":"Belkouchi","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2024.114020_bib13","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"van Griethuysen","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2024.114020_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J Chiropr Med"},{"key":"10.1016\/j.ejca.2024.114020_bib15","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/annonc\/mdf034","article-title":"Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients","volume":"13","author":"K\u00f6hne","year":"2002","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2024.114020_bib16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/jso.24678","article-title":"The prognostic utility of the \u201cTumor Burden Score\u201d based on preoperative radiographic features of colorectal liver metastases","volume":"116","author":"Sasaki","year":"2017","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114020_bib17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/XCS.0000000000000094","article-title":"Machine learning approach to stratifying prognosis relative to tumor burden after resection of colorectal liver metastases: an international cohort analysis","volume":"234","author":"Paro","year":"2022","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejca.2024.114020_bib18","first-page":"1006","article-title":"Individual data meta-analysis for the study of survival after pulmonary metastasectomy in colorectal cancer patients: A history of resected liver metastases worsens the prognosis","volume":"44","author":"Zabaleta","year":"2018","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.ejca.2024.114020_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-021-00564-3","article-title":"Tumour burden and efficacy of immune-checkpoint inhibitors","volume":"19","author":"Dall\u2019Olio","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2024.114020_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2019.10.002","article-title":"Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors","volume":"46","author":"Hopkins","year":"2019","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2024.114020_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000645","article-title":"Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study","volume":"8","author":"Chardin","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2024.114020_bib22","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00259-019-04615-x","article-title":"Baseline metabolic tumor burden on FDG PET\/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors","volume":"47","author":"Seban","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejca.2024.114020_bib23","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab","volume":"24","author":"Joseph","year":"2018","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2024.114020_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005092","article-title":"Imaging endpoints for clinical trial use: a RECIST perspective","volume":"10","author":"Liti\u00e8re","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924006762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924006762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T04:10:21Z","timestamp":1727410221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924006762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":24,"alternative-id":["S0959804924006762"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114020","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114020"}}